A citation-based method for searching scientific literature

Li Ma, Haoyang Li, Dongpo Wang, Ying Hu, Mengjun Yu, Quan Zhang, Na Qin, Xinyong Zhang, Xi Li, Hui Zhang, Yuhua Wu, Jialin Lv, Xinjie Yang, Ruoying Yu, Shucai Zhang, Jinghui Wang. Front Oncol 2021
Times Cited: 2







List of co-cited articles
3 articles co-cited >1



Times Cited
  Times     Co-cited
Similarity


EGFR mutation tracking predicts survival in advanced EGFR-mutated non-small cell lung cancer patients treated with osimertinib.
Anna Buder, Maximilian J Hochmair, Ulrike Setinek, Robert Pirker, Martin Filipits. Transl Lung Cancer Res 2020
14
100

From the beginning to resistance: Study of plasma monitoring and resistance mechanisms in a cohort of patients treated with osimertinib for advanced T790M-positive NSCLC.
Paola Bordi, Marzia Del Re, Roberta Minari, Eleonora Rofi, Sebastiano Buti, Giuliana Restante, Anna Squadrilli, Stefania Crucitta, Chiara Casartelli, Letizia Gnetti,[...]. Lung Cancer 2019
24
100

Clearing of circulating tumour DNA predicts clinical response to osimertinib in EGFR mutated lung cancer patients.
Eva Boysen Fynboe Ebert, Tine McCulloch, Karin Holmskov Hansen, Hanne Linnet, Boe Sorensen, Peter Meldgaard. Lung Cancer 2020
11
100

Analysis of circulating tumour DNA to identify patients with epidermal growth factor receptor-positive non-small cell lung cancer who might benefit from sequential tyrosine kinase inhibitor treatment.
Mariano Provencio, Roberto Serna-Blasco, Fabio Franco, Virgina Calvo, Ana Royuela, Milda Auglytė, Alfredo Sánchez-Hernández, María de Julián Campayo, Carlos García-Girón, Manuel Dómine,[...]. Eur J Cancer 2021
6
50

Association Between Plasma Genotyping and Outcomes of Treatment With Osimertinib (AZD9291) in Advanced Non-Small-Cell Lung Cancer.
Geoffrey R Oxnard, Kenneth S Thress, Ryan S Alden, Rachael Lawrance, Cloud P Paweletz, Mireille Cantarini, James Chih-Hsin Yang, J Carl Barrett, Pasi A Jänne. J Clin Oncol 2016
560
50

Tumor volume determines the feasibility of cell-free DNA sequencing for mutation detection in non-small cell lung cancer.
Tatsuo Ohira, Kazuko Sakai, Jun Matsubayashi, Naohiro Kajiwara, Masatoshi Kakihana, Masaru Hagiwara, Masaaki Hibi, Koichi Yoshida, Junichi Maeda, Keishi Ohtani,[...]. Cancer Sci 2016
25
50

Evolution and Clinical Impact of EGFR Mutations in Circulating Free DNA in the BELIEF Trial.
Miguel-Angel Molina-Vila, Rolf A Stahel, Urania Dafni, Núria Jordana-Ariza, Ariadna Balada-Bel, Mónica Garzón-Ibáñez, Beatriz García-Peláez, Clara Mayo-de-Las-Casas, Enriqueta Felip, Alessandra Curioni Fontecedro,[...]. J Thorac Oncol 2020
13
50

Predicting osimertinib-treatment outcomes through EGFR mutant-fraction monitoring in the circulating tumor DNA of EGFR T790M-positive patients with non-small cell lung cancer (WJOG8815L).
Kazuko Sakai, Takayuki Takahama, Mototsugu Shimokawa, Koichi Azuma, Masayuki Takeda, Terufumi Kato, Haruko Daga, Isamu Okamoto, Hiroaki Akamatsu, Shunsuke Teraoka,[...]. Mol Oncol 2021
2
50

Longitudinal monitoring of EGFR mutations in plasma predicts outcomes of NSCLC patients treated with EGFR TKIs: Korean Lung Cancer Consortium (KLCC-12-02).
Ji Yun Lee, Xu Qing, Wei Xiumin, Bai Yali, Sangah Chi, So Hyeon Bak, Ho Yun Lee, Jong-Mu Sun, Se-Hoon Lee, Jin Seok Ahn,[...]. Oncotarget 2016
114
50

Screening for epidermal growth factor receptor mutations in lung cancer.
Rafael Rosell, Teresa Moran, Cristina Queralt, Rut Porta, Felipe Cardenal, Carlos Camps, Margarita Majem, Guillermo Lopez-Vivanco, Dolores Isla, Mariano Provencio,[...]. N Engl J Med 2009
50

Correlation between progression-free survival, tumor burden, and circulating tumor DNA in the initial diagnosis of advanced-stage EGFR-mutated non-small cell lung cancer.
Yunkyoung Lee, Sojung Park, Woo Sung Kim, Jae Cheol Lee, Se Jin Jang, Jene Choi, Chang-Min Choi. Thorac Cancer 2018
35
50

Longitudinal monitoring of somatic genetic alterations in circulating cell-free DNA during treatment with epidermal growth factor receptor-tyrosine kinase inhibitors.
Eiji Iwama, Kazuko Sakai, Noriko Hidaka, Koji Inoue, Akiko Fujii, Noriaki Nakagaki, Keiichi Ota, Ryo Toyozawa, Koichi Azuma, Keita Nakatomi,[...]. Cancer 2020
16
50

EGFR mutation detection in circulating cell-free DNA of lung adenocarcinoma patients: analysis of LUX-Lung 3 and 6.
Yi-Long Wu, Lecia V Sequist, Cheng-Ping Hu, Jifeng Feng, Shun Lu, Yunchao Huang, Wei Li, Mei Hou, Martin Schuler, Tony Mok,[...]. Br J Cancer 2017
54
50

Effect of Osimertinib and Bevacizumab on Progression-Free Survival for Patients With Metastatic EGFR-Mutant Lung Cancers: A Phase 1/2 Single-Group Open-Label Trial.
Helena A Yu, Adam J Schoenfeld, Alex Makhnin, Rachel Kim, Hira Rizvi, Dana Tsui, Christina Falcon, Brian Houck-Loomis, Fanli Meng, Julie Li Yang,[...]. JAMA Oncol 2020
45
50

Detection of activating and acquired resistant mutation in plasma from EGFR-mutated NSCLC patients by peptide nucleic acid (PNA) clamping-assisted fluorescence melting curve analysis.
Chang Gon Kim, Hyo Sup Shim, Min Hee Hong, Yoon Jin Cha, Su Jin Heo, Hyung Soon Park, Jee Hung Kim, Jin Gu Lee, Chang Young Lee, Byoung Chul Cho,[...]. Oncotarget 2017
16
50

Gefitinib Plus Chemotherapy Versus Chemotherapy in Epidermal Growth Factor Receptor Mutation-Positive Non-Small-Cell Lung Cancer Resistant to First-Line Gefitinib (IMPRESS): Overall Survival and Biomarker Analyses.
Tony S K Mok, Sang-We Kim, Yi-Long Wu, Kazuhiko Nakagawa, Jin-Ji Yang, Myung-Ju Ahn, Jie Wang, James Chih-Hsin Yang, You Lu, Shinji Atagi,[...]. J Clin Oncol 2017
88
50

Evolution and clinical impact of co-occurring genetic alterations in advanced-stage EGFR-mutant lung cancers.
Collin M Blakely, Thomas B K Watkins, Wei Wu, Beatrice Gini, Jacob J Chabon, Caroline E McCoach, Nicholas McGranahan, Gareth A Wilson, Nicolai J Birkbak, Victor R Olivas,[...]. Nat Genet 2017
283
50

Clinical significance of monitoring EGFR mutation in plasma using multiplexed digital PCR in EGFR mutated patients treated with afatinib (West Japan Oncology Group 8114LTR study).
Hiroaki Akamatsu, Yasuhiro Koh, Isamu Okamoto, Daichi Fujimoto, Akihiro Bessho, Koichi Azuma, Satoshi Morita, Nobuyuki Yamamoto, Kazuhiko Nakagawa. Lung Cancer 2019
15
50

Erlotinib versus gemcitabine/cisplatin in Chinese patients with EGFR mutation-positive advanced non-small-cell lung cancer: Crossover extension and post-hoc analysis of the ENSURE study.
Yi-Long Wu, Caicun Zhou, Shun Lu, Shukui Qin, Hongming Pan, Gang Wu, Ying Cheng, Xiaoqing Liu, Baohui Han, Yunzhong Zhu,[...]. Lung Cancer 2019
5
50

Dynamics of EGFR Mutation Load in Plasma for Prediction of Treatment Response and Disease Progression in Patients With EGFR-Mutant Lung Adenocarcinoma.
Álvaro Taus, Laura Camacho, Pedro Rocha, Max Hardy-Werbin, Lara Pijuan, Gabriel Piquer, Eva López, Alba Dalmases, Raquel Longarón, Sergi Clavé,[...]. Clin Lung Cancer 2018
31
50

Metastatic non-small cell lung cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up.
D Planchard, S Popat, K Kerr, S Novello, E F Smit, C Faivre-Finn, T S Mok, M Reck, P E Van Schil, M D Hellmann,[...]. Ann Oncol 2018
587
50

Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement.
David Moher, Alessandro Liberati, Jennifer Tetzlaff, Douglas G Altman. PLoS Med 2009
50


Outcomes in patients with non-small-cell lung cancer and acquired Thr790Met mutation treated with osimertinib: a genomic study.
Chia-Chi Lin, Jin-Yuan Shih, Chong-Jen Yu, Chao-Chi Ho, Wei-Yu Liao, Jih-Hsing Lee, Tzu-Hsiu Tsai, Kang-Yi Su, Min-Shu Hsieh, Yih-Leong Chang,[...]. Lancet Respir Med 2018
85
50

The predictive and prognostic significance of liquid biopsy in advanced epidermal growth factor receptor-mutated non-small cell lung cancer: A prospective study.
P N Ding, T M Becker, V J Bray, W Chua, Y F Ma, D Lynch, J Po, A W S Luk, N Caixeiro, P de Souza,[...]. Lung Cancer 2019
15
50

Phase I Study of the Efficacy and Safety of Ramucirumab in Combination with Osimertinib in Advanced T790M-positive EGFR-mutant Non-small Cell Lung Cancer.
Helena A Yu, Luis G Paz-Ares, James Chih-Hsin Yang, Ki Hyeong Lee, Pilar Garrido, Keunchil Park, Joo-Hang Kim, Dae Ho Lee, Huzhang Mao, Sameera R Wijayawardana,[...]. Clin Cancer Res 2021
17
50

Re-biopsy status among non-small cell lung cancer patients in Japan: A retrospective study.
Kaname Nosaki, Miyako Satouchi, Takayasu Kurata, Tatsuya Yoshida, Isamu Okamoto, Nobuyuki Katakami, Fumio Imamura, Kaoru Tanaka, Yuki Yamane, Nobuyuki Yamamoto,[...]. Lung Cancer 2016
86
50

Dynamic plasma EGFR mutation status as a predictor of EGFR-TKI efficacy in patients with EGFR-mutant lung adenocarcinoma.
Jeng-Sen Tseng, Tsung-Ying Yang, Chi-Ren Tsai, Kun-Chieh Chen, Kuo-Hsuan Hsu, Meen-Hsin Tsai, Sung-Liang Yu, Kang-Yi Su, Jeremy J W Chen, Gee-Chen Chang. J Thorac Oncol 2015
57
50

Clonal Architecture of EGFR Mutation Predicts the Efficacy of EGFR-Tyrosine Kinase Inhibitors in Advanced NSCLC: A Prospective Multicenter Study (NCT03059641).
Xinghao Ai, Jiuwei Cui, Jiexia Zhang, Rongrong Chen, Wen Lin, Congying Xie, Anwen Liu, Junping Zhang, Weihua Yang, Xiaohua Hu,[...]. Clin Cancer Res 2021
6
50

Detection and Dynamic Changes of EGFR Mutations from Circulating Tumor DNA as a Predictor of Survival Outcomes in NSCLC Patients Treated with First-line Intercalated Erlotinib and Chemotherapy.
Tony Mok, Yi-Long Wu, Jin Soo Lee, Chong-Jen Yu, Virote Sriuranpong, Jennifer Sandoval-Tan, Guia Ladrera, Sumitra Thongprasert, Vichien Srimuninnimit, Meilin Liao,[...]. Clin Cancer Res 2015
340
50

Clinical utility of a blood-based EGFR mutation test in patients receiving first-line erlotinib therapy in the ENSURE, FASTACT-2, and ASPIRATION studies.
Yi-Long Wu, Victor Lee, Chong-Kin Liam, Shun Lu, Keunchil Park, Vichien Srimuninnimit, Jie Wang, Caicun Zhou, Anita Appius, Peter Button,[...]. Lung Cancer 2018
26
50

Clearing of circulating tumour DNA predicts clinical response to first line tyrosine kinase inhibitors in advanced epidermal growth factor receptor mutated non-small cell lung cancer.
Eva Boysen Fynboe Ebert, Tine McCulloch, Karin Holmskov Hansen, Hanne Linnet, Boe Sorensen, Peter Meldgaard. Lung Cancer 2020
11
50


Practical methods for incorporating summary time-to-event data into meta-analysis.
Jayne F Tierney, Lesley A Stewart, Davina Ghersi, Sarah Burdett, Matthew R Sydes. Trials 2007
50

Monitoring EGFR T790M with plasma DNA from lung cancer patients in a prospective observational study.
Naoko Sueoka-Aragane, Nobuyuki Katakami, Miyako Satouchi, Soichiro Yokota, Keisuke Aoe, Kentaro Iwanaga, Kojiro Otsuka, Satoshi Morita, Shinya Kimura, Shunichi Negoro. Cancer Sci 2016
54
50

The T790M resistance mutation in EGFR is only found in cfDNA from erlotinib-treated NSCLC patients that harbored an activating EGFR mutation before treatment.
Christina Demuth, Anne Tranberg Madsen, Britta Weber, Lin Wu, Peter Meldgaard, Boe Sandahl Sorensen. BMC Cancer 2018
10
50


EGFR circulating tumour DNA testing: identification of predictors of ctDNA detection and implications for survival outcomes.
Alexandra Pender, Curtis Hughesman, Elaine Law, Amadea Kristanti, Kelly McNeil, Selina Wong, Tracy Tucker, Ian Bosdet, Sean Young, Janessa Laskin,[...]. Transl Lung Cancer Res 2020
1
100

Evaluation of plasma EGFR mutation as an early predictor of response of erlotinib plus bevacizumab treatment in the NEJ026 study.
Tatsuro Fukuhara, Haruhiro Saito, Naoki Furuya, Kana Watanabe, Shunichi Sugawara, Shunichiro Iwasawa, Yoshio Tsunezuka, Ou Yamaguchi, Prof Morihito Okada, Kozo Yoshimori,[...]. EBioMedicine 2020
14
50

EGFR plasma mutation in prediction models for resistance with EGFR TKI and survival of non-small cell lung cancer.
Thang Thanh Phan, Bich-Thu Tran, Son Truong Nguyen, Toan Trong Ho, Hang Thuy Nguyen, Vu Thuong Le, Anh Tuan Le. Clin Transl Med 2019
11
50

Tissue and Plasma EGFR Mutation Analysis in the FLAURA Trial: Osimertinib versus Comparator EGFR Tyrosine Kinase Inhibitor as First-Line Treatment in Patients with EGFR-Mutated Advanced Non-Small Cell Lung Cancer.
Jhanelle E Gray, Isamu Okamoto, Virote Sriuranpong, Johan Vansteenkiste, Fumio Imamura, Jong Seok Lee, Yong-Kek Pang, Manuel Cobo, Kazuo Kasahara, Ying Cheng,[...]. Clin Cancer Res 2019
46
50

Plasma ctDNA Analysis for Detection of the EGFR T790M Mutation in Patients with Advanced Non-Small Cell Lung Cancer.
Suzanne Jenkins, James C-H Yang, Suresh S Ramalingam, Karen Yu, Sabina Patel, Susie Weston, Rachel Hodge, Mireille Cantarini, Pasi A Jänne, Tetsuya Mitsudomi,[...]. J Thorac Oncol 2017
176
50

Detection of EGFR-Activating and T790M Mutations Using Liquid Biopsy in Patients With EGFR-Mutated Non-Small-Cell Lung Cancer Whose Disease Has Progressed During Treatment With First- and Second-Generation Tyrosine Kinase Inhibitors: A Multicenter Real-Life Retrospective Study.
Roberta Minari, Giulia Mazzaschi, Paola Bordi, Letizia Gnetti, Giorgia Alberti, Annalisa Altimari, Elisa Gruppioni, Francesca Sperandi, Claudia Parisi, Giorgia Guaitoli,[...]. Clin Lung Cancer 2020
12
50

Liquid Biopsy for Advanced NSCLC: A Consensus Statement From the International Association for the Study of Lung Cancer.
Christian Rolfo, Philip Mack, Giorgio V Scagliotti, Charu Aggarwal, Maria E Arcila, Fabrice Barlesi, Trever Bivona, Maximilian Diehn, Caroline Dive, Rafal Dziadziuszko,[...]. J Thorac Oncol 2021
33
50


Genotypic and histological evolution of lung cancers acquiring resistance to EGFR inhibitors.
Lecia V Sequist, Belinda A Waltman, Dora Dias-Santagata, Subba Digumarthy, Alexa B Turke, Panos Fidias, Kristin Bergethon, Alice T Shaw, Scott Gettinger, Arjola K Cosper,[...]. Sci Transl Med 2011
50

Gefitinib treatment in EGFR mutated caucasian NSCLC: circulating-free tumor DNA as a surrogate for determination of EGFR status.
Jean-Yves Douillard, Gyula Ostoros, Manuel Cobo, Tudor Ciuleanu, Rebecca Cole, Gael McWalter, Jill Walker, Simon Dearden, Alan Webster, Tsveta Milenkova,[...]. J Thorac Oncol 2014
341
50

Detection of epidermal growth factor receptor mutations in exhaled breath condensate using droplet digital polymerase chain reaction.
Kazuya Nishii, Kadoaki Ohashi, Tomoki Tamura, Kiichiro Ninomiya, Takehiro Matsubara, Satoru Senoo, Hirohisa Kano, Hiromi Watanabe, Naohiro Oda, Go Makimoto,[...]. Oncol Lett 2020
1
100

Assessment of Resistance Mechanisms and Clinical Implications in Patients With EGFR T790M-Positive Lung Cancer and Acquired Resistance to Osimertinib.
Geoffrey R Oxnard, Yuebi Hu, Kathryn F Mileham, Hatim Husain, Daniel B Costa, Philip Tracy, Nora Feeney, Lynette M Sholl, Suzanne E Dahlberg, Amanda J Redig,[...]. JAMA Oncol 2018
321
50

Circulating tumor DNA clearance predicts prognosis across treatment regimen in a large real-world longitudinally monitored advanced non-small cell lung cancer cohort.
Yong Song, Chengping Hu, Zhanhong Xie, Lin Wu, Zhengfei Zhu, Chuangzhou Rao, Li Liu, Yuan Chen, Naixin Liang, Jun Chen,[...]. Transl Lung Cancer Res 2020
26
50


Co-cited is the co-citation frequency, indicating how many articles cite the article together with the query article. Similarity is the co-citation as percentage of the times cited of the query article or the article in the search results, whichever is the lowest. These numbers are calculated for the last 100 citations when articles are cited more than 100 times.